MA39849A - Souches de listeria utilisées comme vaccin recombinant et procédé de production - Google Patents
Souches de listeria utilisées comme vaccin recombinant et procédé de productionInfo
- Publication number
- MA39849A MA39849A MA039849A MA39849A MA39849A MA 39849 A MA39849 A MA 39849A MA 039849 A MA039849 A MA 039849A MA 39849 A MA39849 A MA 39849A MA 39849 A MA39849 A MA 39849A
- Authority
- MA
- Morocco
- Prior art keywords
- recombinant
- recombinant listeria
- producing
- methods
- same
- Prior art date
Links
- 241000186781 Listeria Species 0.000 title abstract 4
- 229960005486 vaccine Drugs 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 108700026244 Open Reading Frames Proteins 0.000 abstract 2
- 108090000623 proteins and genes Proteins 0.000 abstract 2
- 102000004169 proteins and genes Human genes 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 230000028993 immune response Effects 0.000 abstract 1
- 230000001939 inductive effect Effects 0.000 abstract 1
- 210000004898 n-terminal fragment Anatomy 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/36—Adaptation or attenuation of cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20051—Methods of production or purification of viral material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Genetics & Genomics (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Microbiology (AREA)
- Immunology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Virology (AREA)
- Biotechnology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Cell Biology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
La présente invention concerne des procédés de traitement, de protection contre une tumeur ou un cancer et d'induction d'une réponse immunitaire contre cette tumeur ou ce cancer, comprenant l'étape d'administration à un patient d'une souche de listeria recombinante comportant un acide nucléique codant pour une protéine prfa mutante qui assure la restauration partielle de la fonction prfa.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201461983732P | 2014-04-24 | 2014-04-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
MA39849A true MA39849A (fr) | 2017-03-01 |
Family
ID=54333010
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA039849A MA39849A (fr) | 2014-04-24 | 2015-04-14 | Souches de listeria utilisées comme vaccin recombinant et procédé de production |
Country Status (15)
Country | Link |
---|---|
US (2) | US10258679B2 (fr) |
EP (1) | EP3134510B1 (fr) |
JP (3) | JP7009061B2 (fr) |
KR (2) | KR102359691B1 (fr) |
CN (1) | CN106459887A (fr) |
AU (1) | AU2015250111A1 (fr) |
BR (1) | BR112016024352A2 (fr) |
CA (1) | CA2946716A1 (fr) |
IL (1) | IL248483A0 (fr) |
MA (1) | MA39849A (fr) |
MX (1) | MX2016013985A (fr) |
RU (1) | RU2016145464A (fr) |
SG (2) | SG10202011841WA (fr) |
TW (2) | TWI692525B (fr) |
WO (1) | WO2015164121A1 (fr) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP2683400A4 (fr) | 2011-03-11 | 2014-09-17 | Advaxis | Adjuvants à base de listeria |
SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
WO2015126921A1 (fr) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Immunothérapie multi-cibles dirigée contre un biomarqueur |
WO2015164121A1 (fr) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Souches de listeria utilisées comme vaccin recombinant et procédé de production |
MX2017004729A (es) * | 2014-10-14 | 2018-01-09 | Univ Pennsylvania | Terapia de combinacion para usar en la terapia contra el cancer. |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
IL259931B2 (en) | 2015-12-16 | 2024-02-01 | Gritstone Bio Inc | Identification of neo-antigens, preparation, and use |
SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
CN106978381A (zh) * | 2017-03-23 | 2017-07-25 | 上海理工大学 | prfA基因缺失单核细胞增生李斯特氏菌及制备方法 |
MX2020003100A (es) | 2017-09-19 | 2020-08-20 | Advaxis Inc | Composiciones y metodos para la liofilizacion de bacterias o cepas de listeria. |
CN111465989B (zh) | 2017-10-10 | 2024-06-25 | 磨石生物公司 | 使用热点进行的新抗原鉴别 |
CA3080835A1 (fr) | 2017-10-31 | 2019-05-09 | Pantarhei Bioscience B.V. | Methodes immunotherapeutiques pour traiter et/ou prevenir le cancer du poumon |
CN111630602A (zh) | 2017-11-22 | 2020-09-04 | 磨石肿瘤生物技术公司 | 减少新抗原的接合表位呈递 |
MX2020009405A (es) * | 2018-03-09 | 2021-01-08 | Advaxis Inc | Composiciones y métodos para evaluar la atenuación y la infectividad de cepas de listeria. |
CN110408634B (zh) * | 2018-04-27 | 2021-08-03 | 苏州若泰医药科技有限公司 | 一种非整合李斯特菌疫苗及抗肿瘤免疫应答方法 |
US10973908B1 (en) | 2020-05-14 | 2021-04-13 | David Gordon Bermudes | Expression of SARS-CoV-2 spike protein receptor binding domain in attenuated salmonella as a vaccine |
WO2021259963A1 (fr) | 2020-06-23 | 2021-12-30 | Pandora Endocrine Innovation B.V. | Immunisation contre wnt4 pour le traitement et la prophylaxie du cancer du sein |
WO2023066923A1 (fr) | 2021-10-19 | 2023-04-27 | Rahman Nafis | Contraception masculine |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5830702A (en) | 1990-10-31 | 1998-11-03 | The Trustees Of The University Of Pennsylvania | Live, recombinant listeria monocytogenes and production of cytotoxic T-cell response |
US8791237B2 (en) | 1994-11-08 | 2014-07-29 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of non-hodgkins lymphoma |
US7820180B2 (en) | 2004-09-24 | 2010-10-26 | The Trustees Of The University Of Pennsylvania | Listeria-based and LLO-based vaccines |
US8956621B2 (en) | 1994-11-08 | 2015-02-17 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical dysplasia |
US8114414B2 (en) | 1994-11-08 | 2012-02-14 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of cervical cancer |
US20070264279A1 (en) * | 1994-11-08 | 2007-11-15 | Claudia Gravekamp | Compositions and methods comprising a MAGE-b antigen |
US7662396B2 (en) * | 2001-03-26 | 2010-02-16 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US6051237A (en) | 1994-11-08 | 2000-04-18 | The Trustees Of The University Of Pennsylvania | Specific immunotherapy of cancer using a live recombinant bacterial vaccine vector |
US7794729B2 (en) * | 1994-11-08 | 2010-09-14 | The Trustees Of The University Of Pennsylvania | Methods and compositions for immunotherapy of cancer |
US6099848A (en) | 1997-11-18 | 2000-08-08 | The Trustees Of The University Of Pennsylvania | Immunogenic compositions comprising DAL/DAT double-mutant, auxotrophic, attenuated strains of Listeria and their methods of use |
US9012141B2 (en) | 2000-03-27 | 2015-04-21 | Advaxis, Inc. | Compositions and methods comprising KLK3 of FOLH1 antigen |
EP1303299B1 (fr) | 2000-03-29 | 2010-07-28 | The Trustees of The University of Pennsylvania | Utilisation des peptides prokaryotic pest-like pour augmenter l'immunogénicité des antigènes |
US6855320B2 (en) | 2000-03-29 | 2005-02-15 | The Trustees Of The University Of Pennsylvania | Fusion of non-hemolytic, truncated form of listeriolysin O to antigens to enhance immunogenicity |
US7700344B2 (en) | 2001-03-26 | 2010-04-20 | The Trustees Of The University Of Pennsylvania | Compositions and methods for enhancing the immunogenicity of antigens |
US8771702B2 (en) | 2001-03-26 | 2014-07-08 | The Trustees Of The University Of Pennsylvania | Non-hemolytic LLO fusion proteins and methods of utilizing same |
JP2005527240A (ja) | 2002-05-29 | 2005-09-15 | ザ・レジェンツ・オブ・ザ・ユニバーシティ・オブ・カリフォルニア | 弱毒リステリア種とこれを使用する方法 |
CA2512812A1 (fr) | 2003-01-09 | 2004-07-29 | The Trustees Of The University Of Pennsylvania | Compositions, methodes et trousses renforcant l'immunogenecite d'un vecteur de vaccin bacterien |
US7858097B2 (en) * | 2004-08-13 | 2010-12-28 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free Listeria strains and methods for constructing and using same |
US7855064B2 (en) | 2004-08-13 | 2010-12-21 | The Trustees Of The University Of Pennsylvania | Antibiotic resistance free vaccines and methods for constructing and using same |
DK2942391T3 (en) | 2004-08-13 | 2018-08-27 | Univ Pennsylvania | PROCEDURES FOR THE MANUFACTURE OF ANTIBIOTICS-RESISTANCE-FREE VACCINES |
AU2005295158A1 (en) * | 2004-10-18 | 2006-04-27 | Medimmune, Llc | High cell density process for growth of Listeria |
US7935804B2 (en) | 2006-03-01 | 2011-05-03 | Aduro Biotech | Engineered Listeria and methods of use thereof |
EP2977456B1 (fr) | 2006-08-15 | 2017-10-25 | The Trustees Of The University Of Pennsylvania | Compositions comprenant un hmw-maa et fragments de celui-ci pour le traitement du cancer |
US8268326B2 (en) | 2006-08-15 | 2012-09-18 | The Trustees Of The University Of Pennsylvania | Compositions comprising HMW-MAA and fragments thereof, and methods of use thereof |
WO2008130551A2 (fr) | 2007-04-16 | 2008-10-30 | The Trustees Of The University Of Pennsylvania | Souche de listeria exempte de résistance aux antibiotiques et procédé pour la construction et l'utilisation de celle-ci |
WO2009143085A1 (fr) * | 2008-05-19 | 2009-11-26 | Anza Therapeutics, Inc. | Compositions comportant un mutant prfa de listeria, et leurs procédés d'utilisation |
US20150366955A9 (en) | 2009-11-11 | 2015-12-24 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US9650639B2 (en) | 2008-05-19 | 2017-05-16 | Advaxis, Inc. | Dual delivery system for heterologous antigens |
EP2288379A4 (fr) | 2008-05-19 | 2012-08-08 | Advaxis | Système de double distribution pour des antigènes hétérologues |
US20140234370A1 (en) | 2009-11-11 | 2014-08-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of her2/neu over-expressing tumors |
US9017660B2 (en) | 2009-11-11 | 2015-04-28 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors |
US20120135033A1 (en) | 2008-05-19 | 2012-05-31 | Anu Wallecha | Multiple delivery system for heterologous antigens |
US9084747B2 (en) | 2009-11-11 | 2015-07-21 | Advaxis, Inc. | Compositions and methods for prevention of escape mutation in the treatment of HER2/NEU over-expressing tumors |
KR20110045010A (ko) * | 2008-07-24 | 2011-05-03 | 아두로 바이오테크 | C형 간염의 치료를 위한 조성물 및 방법 |
JP5539411B2 (ja) | 2009-03-04 | 2014-07-02 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | 血管新生因子を含む組成物およびその使用方法 |
US10016617B2 (en) | 2009-11-11 | 2018-07-10 | The Trustees Of The University Of Pennsylvania | Combination immuno therapy and radiotherapy for the treatment of Her-2-positive cancers |
WO2011100754A1 (fr) | 2010-02-15 | 2011-08-18 | The Trustees Of The University Of Pennsylvania | Vaccins à base d'une listeria vivante à titre de thérapie pour le système nerveux central |
US20110305724A1 (en) | 2010-04-19 | 2011-12-15 | Yvonne Paterson | Immunotherapeutic, anti-tumorigenic compositions and methods of use thereof |
WO2012138377A2 (fr) | 2010-10-01 | 2012-10-11 | Trustees Of The University Of Pennsylvania | Utilisation de vecteurs de vaccin de listeria pour renverser l'insensibilité au vaccin chez des individus infectés par des parasites |
WO2012068360A1 (fr) | 2010-11-17 | 2012-05-24 | Aduro Biotech | Procédés et compositions pour l'induction d'une réponse immunitaire vis-à-vis d'egfrviii |
EP2683400A4 (fr) * | 2011-03-11 | 2014-09-17 | Advaxis | Adjuvants à base de listeria |
SG11201405605VA (en) | 2012-03-12 | 2014-10-30 | Advaxis Inc | SUPPRESSOR CELL FUNCTION INHIBITION FOLLOWING <i>LISTERIA</i> VACCINE TREATMENT |
WO2015126921A1 (fr) | 2014-02-18 | 2015-08-27 | Advaxis, Inc. | Immunothérapie multi-cibles dirigée contre un biomarqueur |
CA2940646A1 (fr) | 2014-02-25 | 2015-09-03 | Advaxis, Inc. | Compositions et methodes pour le traitement de tumeurs a surexpression de her2/neu |
CA2941405A1 (fr) | 2014-03-05 | 2015-09-11 | Advaxis, Inc. | Procedes et compositions pour accroitre le rapport des lymphocytes t effecteurs aux lymphocytes t regulateurs |
WO2015164121A1 (fr) | 2014-04-24 | 2015-10-29 | Advaxis, Inc. | Souches de listeria utilisées comme vaccin recombinant et procédé de production |
CN106794234A (zh) | 2014-05-02 | 2017-05-31 | 宾夕法尼亚大学理事会 | 用于治疗her‑2阳性癌症的联合免疫疗法和放疗 |
CN114984228A (zh) | 2014-07-18 | 2022-09-02 | 阿德瓦希斯股份有限公司 | 用于治疗***癌的pd-1拮抗剂和基于李斯特菌的疫苗的组合 |
SG11201700090RA (en) | 2014-07-18 | 2017-02-27 | Advaxis Inc | Listeria-based immunogenic compositions for eliciting anti-tumor responses |
WO2016011320A1 (fr) | 2014-07-18 | 2016-01-21 | Advaxis, Inc. | Système de largage d'antigènes hétérologues bivalent dérivé de listéria |
SG11201700092XA (en) | 2014-07-18 | 2017-02-27 | Advaxis Inc | Recombinant listeria strain expressing heterologous antigen fusion proteins and methods of use thereof |
MX2017004729A (es) | 2014-10-14 | 2018-01-09 | Univ Pennsylvania | Terapia de combinacion para usar en la terapia contra el cancer. |
MA41218A (fr) | 2014-12-19 | 2017-10-24 | Advaxis Inc | Combinaison de vaccin à base de listeria comportant des anticorps anti-ox40 ou anti-gitr |
WO2016126878A2 (fr) | 2015-02-03 | 2016-08-11 | The Trustees Of The University Of Pennsylvania | Immunomodulation reposant sur listeria |
US20160220652A1 (en) | 2015-02-03 | 2016-08-04 | Advaxis, Inc. | Methods of using recombinant listeria vaccine strains in disease immunotherapy |
WO2016126876A2 (fr) | 2015-02-03 | 2016-08-11 | Advaxis, Inc. | Adjuvants à base de listeria |
MA41644A (fr) | 2015-03-03 | 2018-01-09 | Advaxis Inc | Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation |
WO2016154412A2 (fr) | 2015-03-26 | 2016-09-29 | The Trustees Of The University Of Pennsylvania | Combinaison d'un antagoniste de pd-1 et d'un vaccin à base de listeria pour le traitement d'un cancer du pancréas |
US20180104284A1 (en) | 2015-05-13 | 2018-04-19 | Advaxis, Inc. | Immunogenic Listeria-Based Compositions Comprising Truncated Acta-Antigen Fusions And Methods Of Use Thereof |
CN107847611A (zh) | 2015-05-26 | 2018-03-27 | 阿德瓦希斯公司 | 个性化的基于递送载体的免疫疗法及其用途 |
CN108138099A (zh) | 2015-06-24 | 2018-06-08 | 阿德瓦希斯公司 | 用于个性化的基于递送载体的免疫疗法的制造装置和方法 |
MA42841A (fr) | 2015-09-15 | 2018-07-25 | Advaxis Inc | Procédé de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria de recombinaison |
WO2017048850A1 (fr) | 2015-09-15 | 2017-03-23 | Advaxis, Inc. | Compositions immunogènes à base de listeria et procédés pour les utiliser dans la prévention et le traitement du cancer |
AU2016324170A1 (en) | 2015-09-17 | 2018-04-12 | Advaxis, Inc. | Recombinant Listeria vaccine strains and methods of using the same in cancer immunotherapy |
MA43124A (fr) | 2015-10-14 | 2018-09-05 | Advaxis Inc | Souches recombinées vaccinales de listeria et leurs méthodes d'utilisation en immunothérapie anticancéreuse |
WO2017085691A1 (fr) | 2015-11-20 | 2017-05-26 | Advaxis, Inc. | Procédé et dispositif de fabrication d'une formulation immunothérapeutique comprenant une souche de listeria recombinante |
TW201726171A (zh) | 2015-12-16 | 2017-08-01 | 艾***公司 | 以李斯特菌屬為主的免疫治療及其用法 |
CN108884468A (zh) | 2016-01-27 | 2018-11-23 | 阿德瓦希斯公司 | 基于个性化递送载体的免疫疗法及其用途 |
CA3029235A1 (fr) | 2016-07-05 | 2018-01-11 | Advaxis, Inc. | Compositions immunogenes a base de listeria comprenant des antigenes de proteine tumorale de wilms et procedes d'utilisation correspondants |
WO2018085854A1 (fr) | 2016-11-07 | 2018-05-11 | Advaxis, Inc. | Combinaison d'un vaccin à base de listeria avec des anticorps anti-ctla-4 ou anti-cd137 |
SG10202105561PA (en) | 2016-11-30 | 2021-07-29 | Advaxis Inc | Immunogenic compositions targeting recurrent cancer mutations and methods of use thereof |
WO2018102585A1 (fr) | 2016-11-30 | 2018-06-07 | Advaxis, Inc. | Immunothérapie personnalisée en association avec une immunothérapie ciblant des mutations de cancer récurrentes |
WO2018129306A1 (fr) | 2017-01-05 | 2018-07-12 | Advaxis, Inc. | Souches vaccinales de listeria recombinées et leurs méthodes d'utilisation en immunothérapie anticancéreuse |
-
2015
- 2015-04-14 WO PCT/US2015/025690 patent/WO2015164121A1/fr active Application Filing
- 2015-04-14 SG SG10202011841WA patent/SG10202011841WA/en unknown
- 2015-04-14 EP EP15782800.5A patent/EP3134510B1/fr active Active
- 2015-04-14 JP JP2016564032A patent/JP7009061B2/ja active Active
- 2015-04-14 CN CN201580021074.6A patent/CN106459887A/zh active Pending
- 2015-04-14 CA CA2946716A patent/CA2946716A1/fr not_active Abandoned
- 2015-04-14 MX MX2016013985A patent/MX2016013985A/es unknown
- 2015-04-14 AU AU2015250111A patent/AU2015250111A1/en not_active Abandoned
- 2015-04-14 MA MA039849A patent/MA39849A/fr unknown
- 2015-04-14 BR BR112016024352-8A patent/BR112016024352A2/pt not_active Application Discontinuation
- 2015-04-14 RU RU2016145464A patent/RU2016145464A/ru not_active Application Discontinuation
- 2015-04-14 US US15/306,289 patent/US10258679B2/en active Active
- 2015-04-14 KR KR1020167029990A patent/KR102359691B1/ko active IP Right Grant
- 2015-04-14 KR KR1020227003655A patent/KR102491332B1/ko active IP Right Grant
- 2015-04-14 SG SG11201608820WA patent/SG11201608820WA/en unknown
- 2015-04-21 TW TW104112751A patent/TWI692525B/zh not_active IP Right Cessation
- 2015-04-21 TW TW109111533A patent/TWI722858B/zh not_active IP Right Cessation
-
2016
- 2016-10-25 IL IL248483A patent/IL248483A0/en unknown
-
2019
- 2019-02-14 US US16/276,520 patent/US20190240303A1/en not_active Abandoned
-
2020
- 2020-03-18 JP JP2020047632A patent/JP2020099352A/ja not_active Withdrawn
-
2022
- 2022-05-30 JP JP2022087587A patent/JP7300041B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
US20190240303A1 (en) | 2019-08-08 |
US20170042996A1 (en) | 2017-02-16 |
WO2015164121A1 (fr) | 2015-10-29 |
MX2016013985A (es) | 2017-01-11 |
JP7009061B2 (ja) | 2022-01-25 |
KR102491332B1 (ko) | 2023-01-27 |
EP3134510A4 (fr) | 2018-04-25 |
TWI722858B (zh) | 2021-03-21 |
US10258679B2 (en) | 2019-04-16 |
CA2946716A1 (fr) | 2015-10-29 |
KR20160145627A (ko) | 2016-12-20 |
EP3134510A1 (fr) | 2017-03-01 |
CN106459887A (zh) | 2017-02-22 |
KR102359691B1 (ko) | 2022-02-10 |
JP7300041B2 (ja) | 2023-06-28 |
JP2022105768A (ja) | 2022-07-14 |
IL248483A0 (en) | 2016-12-29 |
BR112016024352A2 (pt) | 2018-01-23 |
JP2020099352A (ja) | 2020-07-02 |
TW201546276A (zh) | 2015-12-16 |
KR20220021021A (ko) | 2022-02-21 |
TW202041671A (zh) | 2020-11-16 |
JP2017513502A (ja) | 2017-06-01 |
RU2016145464A (ru) | 2018-05-24 |
AU2015250111A1 (en) | 2016-12-08 |
EP3134510B1 (fr) | 2023-11-01 |
SG10202011841WA (en) | 2021-01-28 |
SG11201608820WA (en) | 2016-11-29 |
TWI692525B (zh) | 2020-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2016013985A (es) | Cepas de vacunas de listeria recombinante y metodos para producir las mismas. | |
MA40228A (fr) | Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser | |
MX2017008187A (es) | Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr. | |
MX2017004729A (es) | Terapia de combinacion para usar en la terapia contra el cancer. | |
MX2017000836A (es) | Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. | |
MX2016011537A (es) | Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras. | |
MX2018004598A (es) | Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer. | |
MX2018011425A (es) | Construcciones de anticuerpos de adn y método para utilizarlas. | |
MX2023002858A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
MX2021014448A (es) | Modulacion de celulas mieloides estimulantes y no estimulantes. | |
MX2018001213A (es) | Nuevos metodos para inducir una respuesta inmunitaria. | |
MX2016010565A (es) | Inmunoterapia del cancer a través de la combinacion de estimulacion inmunatoria local y sistemica. | |
MX2021001098A (es) | Anticuerpos de un solo dominio dirigidos contra antigenos intracelulares. | |
NZ745327A (en) | Whole-cell cancer vaccines and methods for selection thereof | |
MX2019010397A (es) | Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina. | |
MX2019000215A (es) | Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso. | |
MX2017005925A (es) | Metodos de producción de proteínas de cadena doble en bacterias. | |
NZ725212A (en) | Group a streptococcus vaccine | |
ZA202204223B (en) | Vaccination with mica/b alpha 3 domain for the treatment of cancer | |
MX365560B (es) | Proteinas quimericas basadas en cyaa que comprenden un polipeptido heterologo y sus usos en la induccion de respuestas inmunes. | |
MX2023003934A (es) | Antigenos de consenso de filovirus, construcciones de acido nucleico y vacunas realizadas a partir de estos, y metodos para utilizarlos. | |
MX2019007924A (es) | Vacunas contra la influenza. | |
MX2021004453A (es) | Nuevos antigenos y metodos contra el cancer. | |
WO2016011432A3 (fr) | Identification de peptides immunogènes de classe ii du complexe majeur d'histocompatibilité pour une immunothérapie | |
MX2017016438A (es) | Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit. |